These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1124321)

  • 1. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 3. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 5. Alkali-labile regions and strand breaks in DNA from cells treated with daunorubicin.
    Schwartz HS
    J Med; 1976; 7(1):33-46. PubMed ID: 1064678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4'-(9-acridinylamino)methanesulfon-m-anisidide.
    Zwelling LA; Kerrigan D; Michaels S
    Cancer Res; 1982 Jul; 42(7):2687-91. PubMed ID: 6896293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
    Trouet A; Sokal G
    Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection.
    Vecchi A; Mantovani A; Tagliabue A; Spreafico F
    Cancer Res; 1976 Apr; 36(4):1222-7. PubMed ID: 944093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
    Yin MB; Bankusli I; Rustum YM
    Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleolar protein B23 translocation after doxorubicin treatment in murine tumor cells.
    Chan PK; Aldrich MB; Yung BY
    Cancer Res; 1987 Jul; 47(14):3798-801. PubMed ID: 2439199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
    Meriwether WD; Bachur NR
    Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA damage by anthracycline drugs in human leukemia cells.
    Schwartz HS; Kanter PM
    Cancer Lett; 1981 Sep; 13(4):309-13. PubMed ID: 6946856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of N-trifluoroacetyladriamycin-14-valerate and related agents on DNA strand damage and thymidine incorporation in CCRF-CEM cells.
    Kanter PM; Schwartz HS
    Cancer Res; 1979 Feb; 39(2 Pt 1):448-51. PubMed ID: 761217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
    Yokota S; Hara H; Luo Y; Seon BK
    Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.
    Silvestrini R; Lenaz L; Di Fronzo G; Sanfilippo O
    Cancer Res; 1973 Nov; 33(11):2954-8. PubMed ID: 4748447
    [No Abstract]   [Full Text] [Related]  

  • 19. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
    Satyamoorthy K; Perchellet JP
    Cancer Res; 1989 Oct; 49(19):5364-70. PubMed ID: 2475247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.